NCT02919683 2026-01-28Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityDana-Farber Cancer InstitutePhase 2 Active not recruiting30 enrolled 14 charts
NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT03347838 2025-12-12Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former SmokersUniversity of Colorado, DenverPhase 2 Active not recruiting19 enrolled 10 charts
NCT02994069 2025-10-14Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress MarkersUniversity of KentuckyPhase 2 Active not recruiting80 enrolled 11 charts
NCT03765918 2025-08-20MK-3475-689Merck Sharp & Dohme LLCPhase 3 Active not recruiting714 enrolled 90 charts 1 FDA
NCT03085719 2025-02-25Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHNDana-Farber Cancer InstitutePhase 2 Active not recruiting18 enrolled 22 charts
NCT02641093 2024-08-29Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell CarcinomaUniversity of CincinnatiPhase 2 Active not recruiting96 enrolled 12 charts